dc.contributor.author |
Boboyeva Zuhra Nurullayevna |
|
dc.date.accessioned |
2022-12-14T19:28:59Z |
|
dc.date.available |
2022-12-14T19:28:59Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
2181-1326 |
|
dc.identifier.uri |
http://repository.tma.uz/xmlui/handle/1/5257 |
|
dc.description.abstract |
The current outbreak of coronavirus disease (COVID-19) is a global emergency as its rapid
spread and high mortality rate have caused severe disruption. The number of people infected
with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, is rapidly increasing worldwide. Patients with COVID-19 may develop pneumonia,
severe symptoms of acute respiratory distress syndrome (ARDS) and multiple organ failure |
en_US |
dc.language.iso |
other |
en_US |
dc.publisher |
Uzbekistan,Tashkent |
en_US |
dc.subject |
coronavirus infection, pathogenesis, acute respiratory syndrome, G. lucidum, Alkhadaya. |
en_US |
dc.title |
PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2. |
en_US |
dc.type |
Article |
en_US |